IRVINE, CA, and HERSTAL, BELGIUM, November 26, 2014 – 8:00 AM CET – MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that it received the following notification of significant shareholdings, in accordance with the Belgian Act of May 2, 2007 on the disclosure of significant shareholdings in issuers of which the shares are admitted to trading on a regulated market.
Shareholdings after actively crossing the transparency threshold:
Edmond de Rothschild Investment Partners S.A.S.informed MDxHealth on November 24, 2014 that, as of November 18, 2014, its participation in MDxHealth fell below the threshold of 3% of the outstanding shares. Edmond de Rothschild Investment Partners now owns 1,001,288 shares, i.e. 2.66 % of the outstanding shares of MDxHealth. Edmond de Rothschild Investment Partners is part of the group Edmond de Rothschild. For further information, reference is made to the information published on MDxHealth’s website (http://www.mdxhealth.com/investors/shareholder-information).
MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
|Dr. Jan Groen, CEO||Mike Sinclair (Media)|
|US: +1 949 812 6979||UK: +44 20 7318 2955|
|BE: +32 4 364 20 70||Cell:+44 7968 022075|
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.